Betta Pharmaceuticals Co., Ltd.

Meryx, Inc.

Zongquan Li

Fei Wang

Weihe Zhang

Xiaodong Wang

Wei Long

Shaojing Hu

Xiangyong Liu

Changlong Han

The invention relates to new crystal forms of compound (trans)-4-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) cyclohexanol trihydrochloride, its hydrate, or solvate, as shown in Formula I. The invention also relates to methods for preparation of the described compound, crystal form, and related intermediate compounds, as well as pharmaceutical compositions containing the compounds. Further described is, the use of the compounds or crystal forms in the production of a medicament for the treatment of a disease, symptom, or condition, or the use in treatment of a disease, symptom or condition.

Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications

The present invention relates to the technical field of medicine, and specifically provides methods for preparing Icotinib, Icotinib hydrochloride, and intermediates thereof. These methods avoid the use of phosphorus oxychloride, thereby greatly reducing the emission of pollutants, which is of major benefits to the economy and environment.

Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof

Growing community of inventors

Zhejiang, China

Zongquan Li